Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China - Scorecard - MDSpire
Advertisement
Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China
Clinical Scorecard: Immune Recovery After Transitioning from EFV-Based Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Immunological Non-Responders: A 144-Week Cohort Study in China
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Virologically suppressed INRs receiving long-term ART (≥4 years) with CD4 counts <350 cells/μL.
Care Setting
Key Highlights
Add specific numerical values for immune reconstitution rates at weeks 48 and 144.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Assess CD4 cell counts and immune reconstitution rates at regular intervals (e.g., every 3 months) post-switch.
Risks
Patient & Prescribing Data
Switching to BIC/FTC/TAF may enhance immune recovery in selected INR populations based on age and duration of ART.
Clinical Best Practices
Consider ART regimen optimization for INRs based on individual patient factors such as age, comorbidities, and previous ART history.
